A Pilot Study on the Comparison between Planning Target Volume-based Intensity-Modulated Proton Therapy Plans and Robustly Optimized Intensity-Modulated Proton Therapy Plans

A Single-Institution Prospective Study To Evaluate the Safety and Efficacy of Real- Time Image-Gated Spot-Scanning Proton Therapy (RGPT) for Prostate Cancer

Purpose

In real-time image-gated spot-scanning proton therapy (RGPT), the dose distribution is distorted by gold fiducial markers placed in the prostate. Distortion can be suppressed by using small markers and more than 2 fields, but additional fields may increase the dose to organs at risk. Therefore, we conducted a prospective study to evaluate the safety and short-term clinical outcome of RGPT for prostate cancer.

Methods and Materials

Based on the previously reported frequency of early adverse events (AE) and the noninferiority margin of 10%, the required number of cases was calculated to be 43 using the one-sample binomial test by the Southwest Oncology Group statistical tools with the one-sided significance level of 2.5% and the power 80%. Patients with localized prostate cancer were enrolled and 3 to 4 pure gold fiducial markers of 1.5-mm diameter were inserted in the prostate. The prescribed dose was 70 Gy(relative biologic effectiveness) in 30 fractions, and treatment was performed with 3 fields from the left, right, and the back, or 4 fields from either side of slightly anterior and posterior oblique fields. The primary endpoint was the frequency of early AE (≥grade 2) and the secondary endpoint was the biochemical relapse-free survival rate and the frequency of late AE.

Results

Forty-five cases were enrolled between 2015 and 2017, and all patients completed the treatment protocol. The median follow-up period was 63.0 months. The frequency of early AE (≥grade 2) was observed in 4 cases (8.9%), therefore the noninferiority was verified. The overall 5-year biochemical relapse-free survival rate was 88.9%. As late AE, grade 2 rectal bleeding was observed in 8 cases (17.8%).

Conclusions

The RGPT for prostate cancer with 1.5-mm markers and 3- or 4- fields was as safe as conventional proton therapy in early AE, and its efficacy was comparable with previous studies.

An uncertainty-incorporated method for fast beam angle selection in intensity-modulated proton therapy

Aim

We propose a novel metric called ψ - score to rank the Intensity Modulated Proton Therapy (IMPT) beams in the order of their optimality and robustness. The beams ranked based on this metric were accordingly chosen for IMPT optimization. The objective of this work is to study the effectiveness of the proposed method in various clinical cases.

Methods and Materials

We have used Pinnacle TPS (Philips Medical System V 16.2) for performing the optimization. To validate our approach, we have applied it in four clinical cases: Lung, Pancreas, Prostate+Node and Prostate. Basically, for all clinical cases, four set of plans were created using Multi field optimization (MFO) and Robust Optimization (RO) with same clinical objectives, namely (1) Conventional angle plan without Robust Optimization (CA Plan), (2) Suitable angle Plan without Robust Optimization (SA Plan), (3) Conventional angle plan with Robust Optimization (CA-RO Plan), (4) Suitable angle Plan with Robust Optimization (SA-RO Plan). Initial plan was generated with 20 equiangular beams starting from the gantry angle of 0°. In the corresponding SA Plan and SA-RO Plan, the beam angles were obtained using the guidance provided by ψ - score.

Results

All CA plans were compared against the SA plans in terms of Dose distribution, Dose volume histogram (DVH) and percentage of dose difference. The results obtained from the clinical cases indicate that the plan quality is considerably improved without significantly compromising the robustness when the beam angles are optimized using the proposed method. It takes approximately 10-15 min to find the suitable beam angles without Robust Optimization (RO), while it takes approximately 20-30 min to find the suitable beam angles with RO. However, the inclusion of RO in BAO did not result in a change in the final beam angles for anatomies other than lung.

Conclusion

The results obtained in different anatomic sites demonstrate the usefulness of our approach in improving the plan quality by determining optimal beam angles in IMPT.

Predicting the complexity of head-and-neck volumetric-modulated arc therapy planning using a radiation therapy planning quality assurance software

Background/Aim

The more complex the treatment plan, the higher the possibility of errors in dose verification. Recently, a treatment planning quality assurance (QA) software (PlanIQ) with a function to objectively evaluate the quality of volumetric-modulated arc therapy (VMAT) treatment plans by scoring and calculating the ideal dose-volume histogram has been marketed. This study aimed to assess the association between the scores of ideal treatment plans identified using PlanIQ and the results of dose verification and to investigate whether the results of dose verification can be predicted based on the complexity of treatment plans.

Materials and methods

Dose verification was performed using an ionization chamber dosimeter, a radiochromic film, and a three-dimensional dose verification system, Delta4 PT. Correlations between the ideal treatment plan scores obtained by PlanIQ and the results of the absolute dose verification and dose distribution verification were obtained, and it was examined whether dose verifications could be predicted from the complexity of the treatment plans.

Results

Even when the score from the ideal treatment plan was high, the results of absolute dose verification and dose distribution verification were sometimes poor. However, even when the score from the ideal treatment plan was low, the absolute volume verification and dose distribution verification sometimes yielded good results.

Conclusions

Treatment plan complexity can be determined in advance from the ideal treatment plan score calculated by PlanIQ. However, it is difficult to predict the results of dose verification using an ideal treatment plan.

Robust optimization of VMAT for prostate cancer accounting for geometric uncertainty

The aim of this study was to propose optimal robust planning by comparing the robustness with setup error with the robustness of a conventional planning target volume (PTV)‐based plan and to compare the robust plan to the PTV‐based plan for the target and organ at risk (OAR). Data from 13 patients with intermediate‐to‐high‐risk localized prostate cancer who did not have T3b disease were analyzed. The dose distribution under multiple setup error scenarios was assessed using a conventional PTV‐based plan. The clinical target volume (CTV) and OAR dose in moving coordinates were used for the dose constraint with the robust plan. The hybrid robust plan added the dose constraint of the PTV‐rectum to the static coordinate system. When the isocenter was shifted by 10 mm in the superior–inferior direction and 8 mm in the right‐left and anterior directions, the doses to the CTV, bladder, and rectum of the PTV‐based plan, robust plan, and hybrid robust plan were compared. For the CTV D_99% in the PTV‐based plan and hybrid robust plan, over 95% of the prescribed dose was secured in all directions, except in the inferior direction. There was no significant difference between the PTV‐based plan and the hybrid robust plan for rectum V_70Gy, V_60Gy, and V_40Gy. This study proposed an optimization method for patients with prostate cancer. When the setup error occurred within the PTV margin, the dose robustness of the CTV for the hybrid robust plan was higher than that of the PTV‐based plan, while maintaining the equivalent OAR dose.

Adaptive proton therapy

Radiation therapy treatments are typically planned based on a single image set, assuming that the patient's anatomy and its position relative to the delivery system remains constant during the course of treatment. Similarly, the prescription dose assumes constant biological dose-response over the treatment course. However, variations can and do occur on multiple time scales. For treatment sites with significant intra-fractional motion, geometric changes happen over seconds or minutes, while biological considerations change over days or weeks. At an intermediate timescale, geometric changes occur between daily treatment fractions. Adaptive radiation therapy is applied to consider changes in patient anatomy during the course of fractionated treatment delivery. While traditionally adaptation has been done off-line with replanning based on new CT images, online treatment adaptation based on on-board imaging has gained momentum in recent years due to advanced imaging techniques combined with treatment delivery systems. Adaptation is particularly important in proton therapy where small changes in patient anatomy can lead to significant dose perturbations due to the dose conformality and finite range of proton beams. This review summarizes the current state-of-the-art of on-line adaptive proton therapy and identifies areas requiring further research.